HCPLive

Related Tags

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Most Popular

Recommended Reading

Many breast cancer patients who are eligible for breast-conserving surgery still choose to have the entire breast removed, according to research scheduled for presentation Thursday at the annual meeting of the American Surgical Association, held from April 23 to 25 in San Diego.
Two new devices may eventually lead to more accurate, less toxic methods of predicting how well a specific cancer drug might work on an individual's cancer, researchers report. Findings from both studies were published in the April 22 issue of Science Translational Medicine.
Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation, and women with estrogen receptor-negative breast cancer and a BRCA1 mutation should undergo the procedure shortly after diagnosis, according to research published online April 23 in JAMA Oncology.
For older women with breast cancer, low self-rated health and limited walking ability predict worse all-cause survival at five and 10 years, according to a study published in the April issue of the Journal of the American Geriatrics Society.
$vAR$